Bock, Allison M. http://orcid.org/0000-0002-3174-8877
Gile, Jennifer J. http://orcid.org/0000-0001-6972-7986
Larson, Melissa C.
Poonsombudlert, Kittika
Tawfiq, Reema K.
Maliske, Seth
Maurer, Matthew J. http://orcid.org/0000-0002-1867-0526
Kabat, Brian F.
Paludo, Jonas http://orcid.org/0000-0002-7350-5531
Inwards, David J.
Ayyappan, Sabarish
Link, Brian K.
Ansell, Stephen M. http://orcid.org/0000-0003-1244-6758
Habermann, Thomas M. http://orcid.org/0000-0003-3532-9132
Witzig, Thomas E. http://orcid.org/0000-0002-4215-6500
Nowakowski, Grzegorz S. http://orcid.org/0000-0002-6955-9393
Cerhan, James R. http://orcid.org/0000-0002-7482-178X
Farooq, Umar http://orcid.org/0000-0001-7891-9891
Wang, Yucai http://orcid.org/0000-0002-1576-8341
Funding for this research was provided by:
NIH, NCI
Article History
Received: 12 July 2023
Revised: 10 October 2023
Accepted: 1 November 2023
First Online: 13 November 2023
Competing interests
: Allison Bock: none; Jennifer Gile: none; Reema Tawfiq: none; Kittika Poonsombudlert: none; Brian Kabat: none; David Inwards: none. Melissa Larson: Research funding (to institution): Genentech, Genmab. Seth Maliske: Advisory board: Janssen, BMS. Matthew Maurer: Advisory board (compensation to institution): Adaptive Biotechnologies, Genmab; Research funding (to institution)<i>:</i> BMS, Morphosys, Roche/Genentech. Jonas Paludo: Research funding (to institution): Karyopharm, Biofourmis; Advisory board (compensation to institution): Abbvie. Yucai Wang: Research funding (to institution): Incyte, InnoCare, LOXO Oncology, Eli Lilly, MorphoSys, Novartis, Genentech, Genmab, Advisory board (compensation to institution): Eli Lilly, LOXO Oncology, TG Therapeutics, Incyte, InnoCare, Kite, Jansen, BeiGene; Consultancy (compensation to institution): Innocare, AbbVie, Honorarium (to institution): Kite. James Cerhan: Research funding (to institution): Genentech, Genmab, NanoString; Advisory board (compensation to institution): Genentech; SMB (personal compensation): Protagonist Therapeutics. Thomas Habermann: Data Monitoring Committee: Seagen, Tess Therapeutics, Eli Lilly & Co.; Scientific Advisory Board (no personal compensation): Morpohsys, Incyte, Beigene, Loxo Oncology; Research funding (to institution): Genentech, Sorrento, BMS. Sabarish Ayyappan: Advisory board (compensation to institution): TG therapeutics, Seattle genetics, Intellisphere, Fate Therapeutics, Beigene, Astra zeneca, Abbvie; Consultancy (compensation to institution): TG therapeutics, Intellisphere; Speaker’s Bureau: Total CME. Stephen Ansell: Research funding (to institution): SeaGen, Takeda, BMS, Regeneron, Affimed, Pfizer, ADC Therapeutics. Thomas Witzig: Research funding (to institution): Karyopharm, Kura Oncology; Advisory board (compensation to institution): ADC Therapeutics; Honoraria: Curio Science. Grzegorz Nowakowsi: Research funding (to institution): BMS/Celgene, MorphoSys AG; Consultancy (compensation to institution): AbbVie, ADC Therapeutics, Blueprint Medicines Corporation, Bantam Pharmaceutical LLC, BMS/Celgene, Curis, Inc, Debiopharm, F. Hoffmann-La Roche Ltd, Genentech, Incyte, Karyopharm Therapeutics, MEI Pharma, MorphoSys AG, Kite Pharma Inc, Kymera Therapeutics, Ryvu Therapeutics, Selvita, TG Therapeutics, Zai lab limited; Advisory board (compensation to institution): Karyopharm Therapeutics, Ryvu Therapeutics, Fate Therapeutics. Umar Farooq: Research funding (to institution); Checkmate pharma, Advisory board (compensation to institution): MorphoSys, Caribou pharma; Consultancy (compensation to institution): MorphoSys Honoraria: Kite, A Gilead Company, Caribou Pharma.